EntryPoint Capital’s Neurocrine Biosciences NBIX Stock Holding History

EntryPoint Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,704	Closed	-$883K	–	901
2026 Q1	$883K	Buy	6,704 +1,835	+38%	+$243K	0.26%	72
2025 Q4	$691K	Buy	4,869 +3,343	+219%	+$484K	0.27%	77
2025 Q3	$214K	Buy	+1,526	New	+$207K	0.08%	525
2024 Q2	–	Sell	-516	Closed	-$71.2K	–	1694
2024 Q1	$71.2K	Buy	516 +223	+76%	+$30.5K	0.06%	594
2023 Q4	$38.6K	Buy	+293	New	+$33.7K	0.04%	840

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EntryPoint Capital's NBIX Position: Q2 2026 in Review

EntryPoint Capital sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 6,704 shares — an estimated $883K sold.

EntryPoint Capital first reported a position in NBIX in Q4 2023 and held it in 5 quarters. The position peaked at $883K in Q1 2026. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

EntryPoint Capital reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
EntryPoint Capital sold 6,704 Neurocrine Biosciences shares in Q2 2026, an estimated $883K.
EntryPoint Capital first reported a position in Neurocrine Biosciences in Q4 2023 and held it in 5 quarters.
EntryPoint Capital's Neurocrine Biosciences position peaked at $883K in Q1 2026.
771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.